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Abstract 
The myeloid-lineage specific enhancer at 363.1 kb upstream of the mouse myeloperoxidase gene [l] has been further characterised. In vitro DNase 
I footprinting experiments revealed three protected sequences (FT-I. -II and -III) in the enhancer, associated with the proteins that are enriched in 
WEHI 3BD’ cells, at which the MPO gene is highly expressed; but not in two non-MPO expressing lymphocytic ell lines. Site-specific mutations 
at each element severely reduced the level of the reporter gene activity in a non-additive manner. This is parallel with either abolishment or alteration 
of the corresponding wild-type protein-DNA interaction in vitro. Consideration of the sequence motifs present in the enhancer suggests that the 
&-elements defined as the in vitro DNase I footprints are likely to be novel. 
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1. In~~uct~on 
Haemopoietic stem cells have the developmental po- 
tential for at least 8 or 9 lymphoid and myeloid lineages. 
The process of the myeloid cell differentiation, which 
converts multipotential progenitor cells into one of six 
mature differentiated cells, i.e. erythrocytes, platelets 
(megakaryocytes), macrophages, neutrophils, eosino- 
phils and basophils, involves temporally regulated ex- 
pression of a number of lineage- and stage-specific genes. 
Understanding the developmental specification of line- 
age and maturation stage associated patterns of gene 
expression in haemopoiesis requires nsight into the con- 
trol of individual lineage-specific ‘marker’ genes for each 
lineage. Within the myeloid lineages, extensive studies 
have described a complex interplay of regulatory cis- 
elements and binding nuclear proteins, in particular for 
the /?-globin enhancer 5’ locus control region in the 
erythrocytic lineage [2]. In this respect, there is, with a 
few recent exceptions [3-S], a marked deficit of informa- 
tion on the granulocytic lineage, a major pathway of 
non-erythroid myeloid cell development. 
The myeloperoxidase gene (MPO) provides an attrac- 
tive model for such studies. MPO gene expression is 
regulated in both a cell-lineage and differentiation-stage 
specific manner during granulopoiesis. The MPO pro- 
tein and bactericidal function are maximally expressed 
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at the promyelocytic stage of granulocytic differentia- 
tion; subsequently as these cells mature into granulo- 
cytes, levels of MPO mRNA rapidly decline, probably as 
a result of both cessation of transcription and decrease 
in stability of MPO mRNA [6]. In the previous report, 
we have identified a myeloid-lineage-specific enhancer at 
approximately 3.1 kb upstream of the mouse MPO gene 
[I] by a transient transfection assay. It functions and 
resides at a DNase I hypersensitive chromatin region in 
WEHI 3BD+ cells, a myelomonocytic cell line [7,8] at 
which the mouse MPO gene is highly expressed, but not 
in two non-MPO expressing lymphocytic cell lines (pre-B 
lymphocytic cell line, 18.8 [9] and pre-T lymphocytic cell 
line, EL-4 [lo]). Functional analysis of the deletion mu- 
tants by a transient-transfection assay, suggests that the 
integrity of the 301 bp BcfllKpnI fragment is required for 
both the function and the orientation-independence of 
the enhancer [I]. In order to delineate the functionally 
important &elements, I have attempted to identify the 
in vitro DNase I footprints specifically associated with 
WEHI 3BD’ cells, and functionally assess the effect of 
the site-specific mutations on the enhancer function as 
well as the wild-type DNA-protein interaction in vitro. 
2. Materials and methods 
2.1. Cell cultures, and the transient transfection assay 
WEHI 3BD’, a myelomonocytic leukaemic ell line [7,8], 18.8 [9] (a 
pre-B cell line derived from BALBlc bone marrow infected with Abel- 
son leukaemia virus, and EL-4 (a C57BL murine T lymphoma (ATCC 
TIB39)) cell line [IO] were cultured as previously described [111. Tran- 
sient transfection by electroporation and luciferase assay were carried 
out as previously described [I]. 
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2.2. Site-speciJic mutagenesis 
Site-specific mutagenesis was carried out essentially according to 
Deng’s method [12] and using Clone-tech Transformer Site-directed 
mutagenesis kit. Two different oligonucleotldes containing partially 
degenerate nucleotlde sequences were used to introduce two sets of 
site-specific mutations within each mdivldual footprint in En-l(Sc/K) 
which contains the 477 bp ScallKpnI fragment upstream of the Tk 
promoter in Pt-109 (Fig. 2). The identlty of the mutants were confirmed 
by sequencing. 
-7.3. Preparation of whole cell extracts and in vitro DNase Ifootprinring 
of sequence specific protein-DNA interactions 
Whole cell extracts were prepared from 2 htres of cells at a concentra- 
tion of 040.8 x 106/ml, essentially according to Manley’s method [13]. 
Proteinase Inhibitors were included in all solutions for the preparation 
and heparin chromatography of whole cell extracts, as well as in vitro 
DNase I foot-printing assays (2 fig/ml aprotinin, I j&ml leupeptm, 1.4 
&ml pepstatin, 0.5 mM benzamidine and 0.5 mM PMSF). The protein 
concentration of extracts was measured by comparing the amido black 
staining density of dotted, dried protein fractions with that of a series 
of dilution of bovine serum albumin on nitro-cellulose paper [14]. Both 
heparm chromatography of the whole extracts and in vitro DNase I 
footprmting assay were performed essentially as described by Dynan 
and TJian [15]. 
3. Results 
3.1. Three WEHI 3 BD’ cell type-speciJic in vitro 
DNase I footprints within the MPO gene enhancer 
The in vitro DNase I footprinting assay [15] for the 
sequence-specific DNA-protein interactions was used to 
identify the candidate cis-elements within the upstream 
enhancer of the mouse MPO gene. The BamHIIXhoI 
fragment from En-l(S/K) was 3’ end-labelled at the XhoI 
site as the probe. As shown in Fig. 1A. there are three 
footprints (FT-I, -11 and -111) associated with the pro- 
teins in 10 ~1 (37 ,ug protein) whole cell extract from 
WEHI 3BD’ cells, but not with 25 ,~l (138 ,ug proteins) 
whole cell extracts of EL-4 cells and 25 ,ul 0.4 M KC1 
elute (15 pug protein) of the heparin chromatography of 
the whole cell extract of 18.8 (N.B. a nuclease activity 
was observed in the whole cell extract of 18.8, and can 
be eliminated in the 0.4 M KC1 elute from the Heparin 
affinity chromatography of the whole cell extract). Being 
aware of the possibility that the absence of these foot- 
prints may be caused by the unsatisfactory quality of the 
protein extracts from both 18.8 and EL-4 cells, I have 
carried out an in vitro DNase I footprinting analysis of 
a 1082 bp SalI-EcoRI fragment which contains both 
promoter and enhancer of the SV 40 early gene (418 bp 
HindIIIHpaII fragment) from plasmid pSG5 [16] and 10 
,~l extracts from each cell line, respectively. The region, 
between 185 and 260 nucleotides from the SalI site con- 
sists of six GC boxes, which are recognised by a ubiqui- 
tously expressed transcription factor, Sp-1 [17] and is 
protected to a comparable xtent from DNase I digestion 
by the proteins from all the three cell lines (Fig. 1C). 
Thus, both the quality and the Sp-1 activity of the pro- 
tein extracts from WEHI 3BD’, 18.8 and EL-4 cells are 
compatible. Therefore, the proteins responsible for the 
occurrence of footprints (FT-I, -11, and -111) in this en- 
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Fig. 1. WEHI 3BD’ cell-type-specific n vitro DNase I footprints (A). 
The 490 bp BamHI-XhoI fragment, containing the 477 bp ScaI-KpnI 
MPO enhancer fragment. was 3’ end-labelled at the XhoI site (the sense 
strand is analysed). The DNase I footprmting experiment was carried 
out with a varying amount of whole cell extract from WEHI 3BD’ cells 
(10 ,uI, 37 pug protein). and EL-4 cells (25 ~1 137 hug protein) and a 0.4 
M KC1 elute from heparin chromatography of the whole cell extract 
of 18.8 cells (25 ~1, 15pg protein). The control was with 12. 5 pg bovine 
serum albumm. Three DNase I footprints are indicated by the shaded 
box on the left side of the autoradiograph. The size marker was pro- 
vided by end-labelled MspI digests of PBR 322 plasmid DNA. (B) A 
1024 bp Sa/IlEcoRI fragment of pSG5 [16], (six Sp I motifs are located 
from 185 to 260 bp from the SafI labelled site) was 3’ end-labelled 
(antisense strand is labelled) and used as the probe for in vitro foot- 
printing. 10~1 of extract of WEHI 3BD’, EL-4 and 18.8 cells were used. 
This fragment contains the 418 bp HzndIIIIHpaII segment of SV 40 
enhancer and early promoter (0.725-0.648 m.u.) of SV 40 DNA and the 
rabbit P-globin intron II. The footprint (approximately 110 bp long 
containing SIX Sp I sites is marked on the right of the autoradiograph. 
The size marker is provided by a sequencing ladder from a known 
sequence. 
hancer are significantly more abundant in WEHI 3BD’ 
cells. These proteins are either absent or too rare to be 
detected by the assay in both El-4 and 18.8 cells. 
3.2. Site-specljic mutations at the sequences of each 
footprint impair the nhancer function 
To search for the function of the c&elements defined 
as the WEHI 3BD’ cell-type-specific footprints (Fig. 1) 
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in the enhancer, I mutated the sequence of each footprint 
and assessed the mutations’ effects on the enhancer func- 
tion by a transient transfection assay. As each footprint 
(16 to 40 bp in length, Fig. 4) is capable of accommodat- 
ing two or more individual sequence-specific DNA-pro- 
tein interactions, I have as a preliminary characterisation 
of the enhancer, used two oligonucleotides, consisting of 
different sets of degenerate sequences to individually in- 
troduce two sets of mutations at each footprint into the 
construct, En-l(Sc/K) (Fig. 2). The luciferase expression 
in the transfected WEHI 3BD’ cells by each mutant was 
measured in parallel with that of Pt-109 and En-l(Sc/K). 
The enhancement in the luciferase expression by all mu- 
tants tested was reduced drastically in comparison to 
that by En-l(Sc/K). Among the mutants tested, two dif- 
ferent types of mutation at each footprint for further 
analysis are listed in Fig. 2. The enhancement in the 
luciferase expression by the mutants ranged from 1.5- to 
15-fold, in comparison to 105-fold by the En-l(Sc/K), 
over the luciferase expression by Pt-109. It is clear that 
the contribution of the DNA-protein interactions at 
each footprint to the enhancer function cannot be de- 
fined in quantity, according to the simple arithmetic role. 
This indicates that a synergistic action contributed by the 
sequence-specific DNA-protein interactions at all the 
three footprints through a complex and yet to be defined 
interplay is required for the enhancer function. 
3.3. The wild-type DNA-protein interactions were 
affected or altered by these mutations 
The further evidence for a direct contribution of the 
c&elements defined as footprints to the enhancer func- 
tion would come from the experiments to assess the 
mutations’ effects on the wild-type DNA-protein inter- 
actions in vitro. Bearing in mind the possibility that the 
mutations’ effect on the enhancer function (Fig. 2) might 
be contributed by a new type DNA-protein interaction 
being fortuitously created by the mutations, I used the 
in vitro DNase I footprinting assay to examine the 
DNA-protein interaction patterns of the whole cell ex- 
tract of WEHI 3BD’ cells with the enhancer fragments 
mo”” up0 DTK 
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from the mutated En-l(Sc/K) (Al and Ala4 for FT-I; Al 1 
and d2a12 for FT-II; and d3b15 and A3c6 for FT-III). 
Although the mutations were created at two different 
parts of FT-I in Al and dla4, respectively, their effect on 
both the function of enhancer (6.5- and 5-fold enhance- 
ment, respectively; Fig. 2) and the DNA-protein interac- 
tions (FT-I was abolished; Fig. 3B) are very similar. At 
mutants All and A2a12 for FT-II, the sequence at the 
centre and 3’ part of FT-II was changed, respectively. As 
shown in Fig. 3E, the mutated part and upstream part 
of FT-II in Al 1 were not protected from DNase I cleav- 
age, while the rest of the footprint remained intact. In 
A2al1, the mutated 3’ part was not protected, while the 
remaining part was fully protected from the DNase I 
digestion. Thus, in FT-II, there are at least two separable 
motifs recognised by protein(s) in WEHI 3BD’. How- 
ever, although mutations at All and A2a12 had very 
different effects on the DNA-protein interaction at FT- 
II, their effect on the function of the wild-type enhancer 
was comparable (lo- and 15-fold enhancement, respec- 
tively; Fig. 2). In the case of FT-III, in A3b15, the central 
10 bp was mutated, while in A3c6, the whole FT-III was 
affected. Both mutants brought the enhancement from 
105-fold of the wild-type enhancer down to 1.5- and 
1.9-fold levels, respectively (Fig. 2) and abolished FT-III 
(Fig. 3D). It was also observed that the protein-DNA 
interactions at the wild-type footprints in each mutant 
(for instance, both FT-II and -III in mutants Al and 
Ala4) were not affected. 
4. Discussion 
4.1. A synergistic action of FT-I, -II and -III is required 
for the function of the MPO gene enhancer 
The transcriptional regulation of eukaryotic genes in- 
volves the combinatorial effects of both lineage-re- 
stricted and common or ubiquitous transcription factors 
[18]. The effect of more than one cis-element (their cog- 
nate transcription factors) on the transcription of a gene 
is often synergistic rather than additive [19]. There is 
Sense strand sequence Luclferase sctivlty of 
mutsntr/Pt-109 
Ifold. k SW1 
FT I (wild typo] 5’ - 3’ lOS.(~~ 8) 
Al 5’ Y 3’ 
Ala4 
6.5,(~3.3 
5' -qGAac 3' 
FT II [wlld type] 5' 
5. lt2.4) 
ccrMaT~TcT- 3' 
All 
A2al2 
;; ccfxfT-mB 3' 15.(d) 
-- 3’ 
FT Ill [wild typo] 5’ 
6.6,(~6) 
-0 3’ 
A3b16 5’ lxTc_cm 3’ 
A3C6 5’ GTSCT~G 3’ 
1.6,(t1.2) 
1.6,(:0.6) 
Fig. 2. Site-specific mutations at the sequence in each footprint and their effects on the luciferase expression in the transfected WEHI 3BD’ cells. 
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Fig. 3. Site-specific mutations and their effects on the corresponding in vitro DNase I footprints 10~1 of the whole cell extract of WEHI 3BIY cells 
was incubated with the single end-k&e&d ~Q~~I-.~~z~I fragment of En-t(ScfK) and ~~uI/~~fuI fragments (conta;oing the 471 Se&@I fmgm~nt~ 
of the following mutants: dI and 61a4 (FT-I), dll and &al 2 (FT-II) and d3bl5 and d3c6 (FT-III) for the in vitro DNase I footprintj~g analysis. 
A sequence ladder was used as a reference for the assignment of the sequence of each footprint. for which the primer had tts 5’ end complimentary 
to the “P-lab&led end of the probe described in (A). The sense strand sequence of the footprmts are Indicated. N.B. Only the results concerning the 
affected footprints is shown, as the rest footprints remain intact in all the cases tested. (A) The in vitro DNase I footprint pattern of the FT-I in 
the wild-type t~mpIate. (B) The absence of FT-1 in the mutated templates, dl and dla4. N.B. Only the sequence ladder of dl is shown. (C) The in 
vitro DNase X footprint pattern of the FT-II and FT-III of the wild-type template. (D) The absence of FT-III m the mutated tempi~tes, d3blS and 
63b6. (E) The absence of FT-II m the mutated templates, LII 1 and .&?a12. The original footprmt regions over the wild-type sequence are shown by 
shaded bars, and the footprints over the mutants by open bars The filled bars show the mutated regions. 
such an example in myeioid lineage. It has been shown 
the ii~~age-sp~~i~~ expression of the chicken ryz&-I gene 
seems to be dete~i~ed by a syner~stic action of myb 
(widely expressed in haemopo~et~~ cells) and NF-M (a 
myeloid-specific member of the CfEBP family of tran- 
scription factors) [4,53. 
The first indication for the synergistic action of the 
&-elements of the three footprints (FT-I, -II and -III) 
responsible for the function of the MPO gene enhancer 
was from a function anaiysis of a set of deletion mutants 
ill. The ~mpai~e~t of the i~teg~ty of the 301 bp Bciff 
KpnI fragment by deletion from either end have severely 
reduced the enhancement in a uon-additive manner 11 f. 
In this report, 1 have showy that the mutations affecting 
the DNA-protein interactions at any one of the three 
footprints impaired the enhancer function in a similar 
non-additive manner f Fig. 2). Furthermore, all the dele- 
tion mutants which have deleterious effects on the en- 
hancer function, described in the previous report [l], 
lack, at least, one of the three footprints (Figs. 1 and 2). 
Therefore, the &~-elements defined as the WEHI 3BD* 
all-ty~-specify footprints are the integral ~rnpa~e~ts 
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of the enhancer, and a synergistic action involving all the 
footprints is essential for the enhancer function. Since 
only the DNA-protein interactions at the mutated foot- 
prints were affected (Fig. 3, and data not shown), the 
protein-protein interactions between the specifically 
bound proteins of the three footprints which is likely to 
be also affected by the mutations at any one of the three 
footprints, may be the key event of the enhancer activity. 
4.2. The novefty of the cis-elements in the MPU gene 
efzhancer? 
Since a large number of the cis-elements have been 
identified and their cognate transcription factors have 
been recently characterised and cloned [20--221, the nov- 
elty of the newly discovered cis-elements can be quickly 
assessed by the sequence homology analysis with a com- 
puter assistance. Three consensuses respectively bound 
by the previously characterised transcription factors, e.g. 
Sp-1, myb and PEA3, are found in the MPO gene en- 
hancer (301 bp L3cJI/K@ fragment; Fig. 4). However, 
irrespective of the MPU gene expression, the binding 
activity of Spl is compatibly among the cell lines studied 
(Fig. IC, and Fig. ?A). The messenger level of Myb is 
also indistinguishable among the three cell lines by 
Northern analysis (unpublished data). PEA3 is not ex- 
pressed in haemopoietic ells [23]. Therefore, these three 
consensuses and their cognate transcription factor are 
not likely to make, if any, direct significant contribution 
to the enhancer function Furthermore, these consen- 
suses are not protected by the proteins of all the three cell 
lines from DNase I digestion in vitro (Fig. 1). Therefore, 
the identifi~~ion of the motifs based on a sequence ho- 
mology does not automatically demonstrate their func- 
tional importance, as recently critically discussed by 
Mikkelsen [24]. However, the lack of a sequence homol- 
ogy with the c&elements bound by the previously de- 
scribed transcription factors [21-231, does suggest that 
the &-elements defined as FT-I, -II, and -111 (Fig. 4), 
recognised by the proteins highly enriched in WEHI 
3BD’” cells might be novel. Current effort to define the 
direct nucleotides contact at each footprint (FT-I. -Ii and 
-III) by using the approaches uch as methylation inter- 
ference [25] and in situ UP-Cn footprinting 1261, will not 
only provide an insight into the nature of the c&elements 
(FT-I, -11 and -III) and their cognate transcription fac- 
tors, but also pave the way for cloning the transcription 
factars involved. 
4.3. The upstream enhancer of the mouse MPO gene and 
the promyeiocytic stage-spec@c expression of the 
mouse MPO gene 
The WEHI 3BD’ cell type specificity of the upstream 
enhancer of the MFU gene has been demonstrated by the 
comparative studies of its DNase I hypersensitivity in 
nuclei [l], the expression of the MPU mRNA [I I]_ the 
function by a transient ransfection assay (Figs. 2 and 31, 
as well as the occurrence of the in vitro DNase I foot- 
prints (Fig. 1). Since, a11 the comparable analyses with 
the two non-myelocytic controls (18.8, for pre-B, and 
EL-4 for pre-T lymphocytic) are negative [I], and the 
lineage identity of all three cell lines are well documented 
[7-lO], this enhancer is likely to be specific to the neutro- 
philic granulocytic lineage on the myeloid differentiation 
pathway. 
The fact that the MPU gene is expressed at the premy- 
elocytic stage ~fgranuIopo~esis in viva, raises an interest- 
ing possibility: the MPU gene enhancer may also be 
specific for the promyelocyti& stage. Indeed, there are 
some supportive preliminary data. The extracts from the 
several non-MPO expressing myeloid cell lines, including 
MEL cells (an erythrocytic cell line [27J), WEHI 3BD- 
cells (a myelomonocytic ell line [7]), and 416 B cells (a 
myeloid progenitor cell line 1281) gave rise to none of the 
three footprints. On the contrary, the whole cell extract 
from a myelomonocytic ell line, NFS-60 {29] where the 
MPU gene does express, gives rise to all the three foot- 
prints (unpublished ata). Since WEHI 3BD” cells have 
a potential to differentiate into neutrophili~ granulocytes 
induced by granulocyte colony stimulating factor [8], 
accompanied with the cessation of the expression of the 
MPO gene, this important issue can be further addressed 
by testing the function of the MPO gene enhancer in the 
induced WEHI 3BD’ cells. 
Recently, another group has reported a positive cis- 
element at several hundred bp upstream of the mouse 
MPO gene which is only functional in a myeloid cell line, 
32D Cl3, but not in ~broblas~i~ ceils 1301. Since no 
haemopoietic ell control has been considered when both 
function of the c&element identified and the in vitro 
sequence-specific DNA-protein interactions were analy- 
fhs primary sequance of tha upstream 
enhancer of the mouse MPO gene 
(Bcl I-Kpn I fragment, 301 bp) 
%!a I- ---176 bp --a 
Fig. 4. The primary sequence of the upstream enhancer of the mouse 
MPG gene. The primary sequence of the upstream enhancer (Bcfl-KpnI, 
301 bp fragment) and three in vitro DNase I footprints (FT-I, -II and 
-III; boxed) are shown. The sites of several relevant restriction enzymes 
are also indicated. Also underlined are consensuses recognrsed by the 
previously characterised transcription factors compiled in references 
[21-231 (the motifs were manually imported into the motif data bank 
in GeneWork, version 2.1 (Intelligenetics Inc., USA). The identified 
motifs within the 301 BeiflKp’pnI fragment were viewed in the motif view. 
Sp-1 (GTT)(GIAKjGCiG~~(GfA)2(GPff myb (T/C~AAC(G~~G 
PEA3 AGGAA(~G~. 
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sed, the functional role of this element in the myelomon- 
ocytic lineage-specific expression of the moue MPO gene 
remains to be seen. However, this &element is clearly 
distinct from the enhancer being characterised in some 
detail in this report. 
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